TOFO Insulin Combination Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

Also called NCT02201004

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 211 participants (enrolled count) (from the registry)
Sponsor
  • Kowa Company, Ltd. Registry lists this organization as a collaborator
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02201004
Other papers using this trial's data
  • Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial Diabetes, obesity & metabolism, 2017-10 DOI, PubMed 28371205, PMC5637911 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02201004. Randomized; double masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2016-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TOFO Insulin Combination Trial
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TOFOGLIFLOZIN CSG452
Intervention (Drug)
insulin
Intervention (Drug)
placebo
Lead sponsor
Sanofi (class: industry)
Collaborator
Kowa Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02201004
Content hash
be6d37bb8ec116ae2d7fbb07a93c2a466123031a60c5fe73a13323d5cc3d63e3